MGA Technologies: the French Ecosystem Serving the Bioproduction of the Future
Chosen to represent the Rhône department at the ‘Grande Exposition du Fabriqué en France’ (Great Exhibition of French Manufacturing) at the French presidential palace, Maison MGA designs technologies in France that will help to transform the life sciences industry, making it safer, more flexible and smarter, with a focus on patient needs.
Medicine in transition
The individual Patient Era
Medicine is undergoing a revolution: messenger RNA vaccines, cell and gene therapies… Each production batch may represent a single patient. No deviation is acceptable.
Quality is no longer controlled only at the end of the chain: it must be guaranteed at every step, every connection, every piece of data.
‘The life sciences industry requires new production models that are safer, more flexible, smarter and capable of serving patients as closely as possible to their needs.’
— Hervé de Malliard, CEO of Maison MGA
🎯 Our goal: to make it possible to manufacture for living, personalised and safe medicines.
The Factory of the Future
Flexible, Automated, Connected
For decades, one medicine = one factory designed solely for it. This model is reaching its limits.
Major innovations are revolutionising industrial organisation:
✅ Single-use systems enable multi-product cleanrooms
✅ Robotisation ensures asepsis by keeping humans away from critical areas.
✅ Digitalisation makes every operation traceable and verifiable.
It is no longer just about production. It is about protecting the integrity of living organisms throughout their entire life cycle.
The MGA ecosystem
Four pillars Supporting the Bioproduction of the Future
Pillar 1 - Mastering Single-Use and Asepsis
The manufacture of living medicines requires constant monitoring of asepsis, from the start of cell culture to final cryopreservation. In single-use systems, every connection counts.
It is in this context that Maison MGA designed the AseptiWeld L, an automated sterile connector developed in collaboration with French industry.
Its role is simple: to preserve the integrity of the closed system, step by step, while facilitating the work of teams in the field.
A reusable blade helps reduce single-use plastic waste while controlling the cost per weld. This device is part of a pragmatic approach to transforming processes to make them more flexible and responsible.
Our goal is to provide a reliable tool that is consistent with the operational requirements of bioproduction sites.
Pillar 2 - Automation and Robotisation of Critical Environments
In pharmaceutical clean rooms, human presence remains one of the greatest risks of contamination.
The stricter requirements of Annex 1 of GMP are leading the industry to rethink the role of operators and to further secure the most sensitive procedures.
For over 40 years, MGA Technologies has been automating repetitive and demanding operations: assembly, aseptic handling, and logistics flows in controlled areas.
Our machines aim to achieve three concrete results:
- Reduce staff exposure to strenuous tasks and risks
- Ensure the repeatability of critical operations
- Support compliance in an increasingly stringent regulatory environment
We work alongside manufacturers to adapt robotisation to the reality of each process, without ever replacing human expertise.
Pillar 3 - Digitalisation and Traceability of Operations
At a time when a batch can represent a patient, the accuracy of the data becomes as important as the quality of the product itself.
To meet this requirement, we draw on the experience of our Mably (France) site, which was designed from the outset as a new-generation factory:
- Zero paper
- Real-time monitoring
- Line reversibility
- ISO 13485 certification, Industry of the Future Showcase and Connected Factory 2024
This expertise is reflected in the design of the equipment: each operation can be automatically documented without adding to the workload of the teams.
Our goal is for quality to be evident by design, rather than verified after the fact.
Pillar 4 - Advanced quality control, as close as possible to the product
In biotherapies, the complexity of living organisms makes control methods more difficult, while expectations in terms of timeframes and precision are increasing.
Manufacturers need to:
- Know the status of the product during cultivation or purification
- Anticipate deviations before they become critical
- Make batch release decisions more reliable
Maison MGA does not perform quality control. Our role is to design and industrialise analytical instruments that can be integrated into automated lines, so that experts can measure what matters, at the right time.
These solutions help to:
- Reduce analysis cycles
- Limit release delays
- Improve the overall robustness of biological processes
At our scale, we seek to bring patient treatment closer together more quickly.
A French industry Committed to Health Sovereignty
MGA is working to ensure that the production of innovative therapies remains within our territory.
We actively contribute to:
- La French Fab
- La French Care
- Territoires d’industrie en beaujolais
- PIIEC Med4Cure – “The Drug Cell”
- France 2030
Because health sovereignty is not a concept. It consists of factories that produce, women and men who manufacture, and an industry that protects life.
Made in France
An industry that trusts in French excellence
Maison MGA was selected to represent the Rhône region at the Élysée as part of the Grande Exposition du Fabriqué en France (Great Exhibition of Made in France).
A clear signal: the technologies that are transforming healthcare are being developed here.